Brought to you by 
DeCODE partners sequence-based clinical diagnostics IP with start-up NextCODE
25 Jul 2022
Executive Summary
Start-up NextCODE Health LLC received exclusive rights over the next five years to Icelandic life sciences company deCODE genetics EHF’s genomics platform, which will allow NextCODE to develop sequence-based clinical diagnostics. The deal is concurrent with deCODE’s spin off of NextCODE, which also received $15mm in Series A financing from Polaris Partners and Arch Venture Partners, and will be led by former deCODE key executives.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DeCODE partners sequence-based clinical diagnostics IP with start-up NextCODE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice